Ken Griffin Annovis Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$5.27 - $15.46 $667,709 - $1.96 Million
126,700 Added 91.88%
264,600 $2.13 Million
Q2 2024

Aug 14, 2024
BUY
$4.82 - $18.01 $100,256 - $374,608
20,800 Added 17.76%
137,900 $794,000
Q1 2024

May 15, 2024
BUY
$8.47 - $18.93 $972,356 - $2.17 Million
114,800 Added 4991.3%
117,100 $1.39 Million
Q4 2023

Feb 14, 2024
BUY
$5.55 - $19.62 $12,765 - $45,126
2,300 New
2,300 $43,000

Others Institutions Holding ANVS

# of Institutions
45
Shares Held
1.16M
Call Options Held
229K
Put Options Held
934K
View Full List

About Annovis Bio, Inc.

ANVS Quotes by TradingView
  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $58M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email